Abstract:
The present invention relates to compounds of formula (I), wherein R is hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, cyano, trifluoromethyl, trifluoromethoxy or lower alkylthio; R is -C(O)O-lower alkyl, isoxazol, 1,2,4-oxadiazol-3-yl or 1,2,4-oxadiazol-5-yl, which rings may be substituted by lower alkyl, trifluoromethyl or cycloalkyl; R is hydrogen, lower alkyl, -(CH2)n-cycloalkyl, -(CH2)n-halogen, -(CH2)n-pyridin-4-yl, or -(CH2)n-phenyl, wherein the phenyl ring may be substituted by one or two substituents selected from the group consisting of lower alkoxy, halogen, -SO2CH3, phenyl, OCF3, nitro, CF3, -NR2, or is -(CH2)n-indolyl, optionally substituted by lower alkyl or lower alkoxy, or is pyrrolidinyl-5-oxo, -C(O)-NR2, -(CH2)n-OH, -(CH2)n-NR2 or -(CH2)n-benzo[1,3]dioxole; R is hydrogen or lower alkyl; and n is 0, 1, 2 or 3; and to their pharmaceutically acceptable acid addition salts. These compounds have a good affinity to the GABA A alpha 5 receptor and they are therefore useful for the treatment of diseases, related to this receptor.
Abstract:
The invention relates to compounds of the general formula (I), wherein R 1 , R 2 are independently from each other hydrogen or C l -C 6 -alkyl; R 3 , R 4 are independently from each other hydrogen or C 1 -C 6 -alkyl; R 5 is halogen, CN, (C 1 -C 6 )-alkyl or (C 1 -C 6 )-alkoxy; n, m or o is 0, 1 or 2; as well as to their pharmaceutically acceptable salts. The compounds may be used for the treatment and prevention of Alzheimer's disease or senile dementia.
Abstract:
This invention relates to N-acylamino aryl derivatives of the general formula (I), wherein R is halogen, halogen-(C1-C6)-alkyl, cyano, C1-C6-alkoxy or halogen-(C1-C6)-alkoxy; R , R , R and R independently from each other are selected from the group consisting of hydrogen, (C1-C6)-alkyl, halogen, halogen-(C1-C6)-alkyl, hydroxy, C1-C6-alkoxy or -CHO; R is hydrogen or C1-C3-alkyl; R , R independently from each other are selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-alkoxy or -COO(C1-C6)alkyl; or R and R form together with the C-atom to which they are attach a C3-C7-cycloalkyl ring; R is -CO-NR R ; -COO(C1-C6)-alkyl, -CN, -NR2 or -NHC(O)R; R and R independently from each other are selected from the group consisting of hydrogen, C1-C6-alkyl, NH2 or hydroxy; R is hydrogen or C1-C6-alkyl; n is 0, 1, 2 or 3. X is -CHRO, -OCHR, -CH2S-, -SCH2-, -CH2CH2-, -CH=CH- or -C=C-; and to pharmaceutically active acid addition salts thereof. It has been found that the compounds of general formula (I) are selective monoamine oxidase B inhibitors and they are therefore useful in the treatment of diseases mediated by monoamine oxidase B inhibitors, for example for the treatment of Alzheimer's disease or senile dementia.
Abstract:
The present invention is concerned with substituted imidazo [1,5-a] [1,2,4] triazolo [1,5-d] [1,4]benzodiazepine derivatives of the following formula (I) wherein R' is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, nitro, cycloalkyl, -O(CH2)mO(CH2)mOH or -C.ident.C-R'; R2 is hydrogen or methyl; R3 is lower alkyl, lower alkyl substituted by halogen, lower alkenyl, lower alkenyl substituted by halogen, lower alkynyl, -(CH2)n-cycloalkyl, -(CR'R")m CH3, or is phenyl, unsubstituted or substituted by halogen, or is pyridinyl or thienyl, unsubstituted or substituted by lower alkyl, or is -(CH2)n-NH-cycloalkyl, lower alkenyl-cycloalkyl, lower alkynyl-(CR'R")mOH, or is lower alkynyl-phenyl, wherein the phenyl ring is unsubstituited or substituted by halogen, CF3, lower alkyl or lower alkoxy; R' is hydrogen or lower alkyl; R" is hydrogen, hydroxy or lower alkyl; n is 0, 1 or 2; m is 1, 2 or 3; o is 1 or 2; and with their pharmaceutically acceptable acid addition salts. It has been found that this class of compounds show high affinity and selectivity for GABA A .alpha. 5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.
Abstract:
Racemic enantiomerically pure 4- pyrrolidino derivatives of formula (I), processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of illness, in particular which is mediated by monoamine oxidase B inhibitors, in particular Alzheimer~s disease or senile dementia.
Abstract:
The present invention is concerned with aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives of formula wherein: R 1 , R 2 , and R 3 are as defined herein and pharmaceutically acceptable acid addition salts thereof. These compounds have high affinity and selectivity for GABA A alpha5 receptor binding sites. The invention also relates to methods for enhancing cognition and treating cognitive disorders like Alzheimer's disease.
Abstract:
Derivados sustituidos de imidazo[1,5a][1,2,4]triazolo[1,5-d][1,4]benzodiazepina de fórmula: **(Ver fórmula)** en la que: R1/R1' son, de manera mutuamente independiente, hidrógeno, hidroxi, alquilo inferior, alquinilo inferior, halógeno, alcoxi inferior, cicloalquilo, o alquilo inferior o alcoxi, sustituidos con halógeno, X es -CH2-, -CH(CH3)-, -CH2O-, -CRR'- o -C(O)-, R2 es -(CH2)n-O-alquilo inferior, halógeno, -NHCH3, N(CH3)C(O)-cicloalquilo, -N(CH3)C(O)-alquilo inferior, N(CH3)S(O2)CH3, -NHC(O)CH2OC(O)CH3, -CF3, cicloalquilo, hidroxi, -CH2OH, ciano, S(O)2CH3, -CH(OH)-alquilo inferior, arilo no sustituido o sustituido con alcoxi nferior, o es un anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, y en el que los anillos pueden 20 encontrarse no sustituidos o encontrarse sustituidos con 1 a 4 sustituyentes seleccionados de entre el grupo que consiste de alquilo inferior, alcoxi inferior, cicloalquilo, =O, CF3, CN, C(O)O-alqilo inferior, bencilo, fenilo, -CH2O-alquilo inferior, CHO o 3-bromo-10-cloro-9H-imidazo[1,525 a][1,2,4]triazolo[1,5-d][1,4]benzodiazepín-6-ilmetil, o es C(O)-O-alquilo inferior, -C(O)NH-(CH2)n-cicloalquilo, C(O)NH-(CH2)n-anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, -C(O)NH-(CH2)nOH, C(O)-anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, no sustituido o sustituido con alquilo inferior, o es -NH-C(O)H o -N(CH3)-C(O)H, -NHC(O)-alquilo inferior, -NH-C(O)-cicloalquilo, -NH-C(O)-Oalquilo inferior, -NH-C(O)-N-dialquilo inferior, -NH-C(O)CH2-O-alquilo inferior o -NH-C(O)-CH2-OH, -NH-(CH2)ncicloalquilo, -NH-(CH2)nS(O)2CH3, -NH-(CH2)n-anillo heterocíclico aromático o no aromático, que contiene entre 1y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, -NH-(CH2)nOH, o X-R2 es alquilo inferior con la excepción de metilo, o es cicloalquilo, no sustituido o sustituido con alquilo inferior o hidroxi, o es un anillo heterocíclico aromático o no aromático, que contiene entre 1 y 3 heteroátomos, seleccionados de entre el grupo que consiste de N, O o S, o es -CHRR', R es hidroxi, y R' es cicloalquilo, alquilo inferior, alquilo inferior sustituido con halógeno, fenilo o piridinilo, R3 es hidrógeno, halógeno, C(O)O-alquilo inferior, CH2OH CHO, alquilo inferior o alquilo inferior sustituido con halógeno, n es 0, 1 ó 2, en la que arilo se refiere a un grupo fenilo, bencilo o naftilo, y ; en la que alquilo inferior se refiere a un grupo alquilo de cadena lineal o ramificada que contiene entre 1 y 7 átomos de carbono, y en la que alcoxi inferior se refiere a un grupo alquilo de cadena lineal o ramificada que contiene entre 1 y 7 átomos de carbono que se encuentra unido mediante un grupo de oxígeno, y en la que alquinilo inferior se refiere a un grupo de carbonos de cadena lineal o ramificada que contiene entre 2 y 7 átomos de carbono, en la que por lo menos un enlace es un triple enlace, y las sales de adición de ácido farmacéuticamente aceptables de los mismos.
Abstract:
The invention relates to compounds of the formula and their pharmaceutically acceptable salts wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase beta inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical compositions containing them.